Harrow Expands Patient Access Program Across Ophthalmic Portfolio

Harrow Initiates Comprehensive Ophthalmic Access Program

Harrow (NASDAQ: HROW), a prominent provider of ophthalmic disease management solutions in North America, recently announced the launch of Harrow Access for All (HAFA). This strategic initiative is designed to expand the company's patient-centric market access model across its comprehensive ophthalmic portfolio, aiming to enhance medication affordability and accessibility for a broader patient base.

Program Details and Rollout Structure

HAFA builds upon the demonstrable success of the VEVYE Access for All (VAFA) initiative, which was introduced in March 2025 for VEVYE® (cyclosporine ophthalmic solution) 0.1%, a treatment for dry eye disease. VAFA successfully drove a 66% growth in VEVYE prescriptions during the second quarter of 2025 by mitigating cost and administrative barriers. HAFA now scales this proprietary model to encompass Harrow's entire offering of branded, authorized generic (AGx), and compounded ophthalmic medications.

The program will introduce a single, unified access point for prescribers and patients through the HarrowAccess.com portal, which is set to launch in phases from late 2025 through 2027. This platform aims to simplify the prescribing process, facilitate prior authorizations, and ensure predictable access to treatments. A key feature of HAFA is its pricing structure, where eligible commercially insured patients may incur out-of-pocket costs as low as $0, with a maximum cap of $59 for all eligible patients, irrespective of their insurance status. Medications will be dispensed via PhilRx, Harrow's specialty pharmacy partner, offering convenient home delivery.

HAFA's implementation is planned in three distinct phases:

Phase 1 (Q4 2025): Will cover the majority of Harrow's specialty product portfolio, including the upcoming launch of BYQLOVI™ (clobetasol propionate ophthalmic suspension) 0.05%.
Phase 2 (First Half of 2026): Will integrate an expanded portfolio of AGx offerings.
Phase 3 (2027): Will extend HAFA across Harrow's full spectrum of specialty, AGx, and compounded medicines.

Market Reaction and Strategic Implications

The launch of HAFA is anticipated to generate a bullish sentiment for Harrow, with expectations of a substantial increase in prescription volume, market share, and revenue across its ophthalmic portfolio. The company, which boasts a market capitalization of $1.71 billion and has reported a 48% revenue growth over the last twelve months, along with a robust gross profit margin of 74.56%, demonstrates strong operational efficiency.

This initiative represents a strategic shift where Harrow appears to be trading immediate margin for long-term volume, a model that often yields favorable economics in the pharmaceutical sector. By addressing affordability and ease of access, HAFA is expected to significantly improve medication adherence and refill rates. The creation of the HarrowAccess.com portal is seen as a mechanism to foster physician loyalty and establish a technical moat within the industry.

Mark L. Baum, Chief Executive Officer of Harrow, underscored the program's significance:

"HAFA will serve as the 'Amazon for Ophthalmology' — a seamless and unified platform, offering white-glove service that allows physicians to focus on patient care rather than managing paperwork."

This perspective highlights the dual benefit of HAFA: enhanced patient access and reduced administrative burdens for healthcare providers.

Broader Context and Future Outlook

The success of the preceding VAFA program, which delivered a 66% sequential prescription growth for VEVYE, provides a strong precedent for HAFA's potential impact. The phased rollout strategy allows Harrow to manage operational complexities while incrementally expanding its revenue base and mitigating implementation risks. Analysts currently project positive net income for Harrow this year, further bolstered by the company's full-year revenue guidance of greater than $280 million.

Looking ahead, the full realization of HAFA by 2027 is expected to solidify Harrow's position in the ophthalmic market and potentially set a new benchmark for patient access models across the pharmaceutical industry. The company's strategic financial initiatives, including a recent $250 million private offering of senior unsecured notes and a new $40 million revolving credit facility, coupled with optimistic price targets from firms like B.Riley ($70) and BTIG ($63), indicate confidence in Harrow's growth trajectory. Investors will closely monitor the initial phases of HAFA's rollout and its impact on prescription volumes and financial results as the program aims to reshape patient access to ophthalmic treatments.